Study finds endogenous utrophin shows promise as treatment for DMD
Mice studies show that the activation of endogenous utrophin is a promising therapeutic strategy in alleviating DMD symptoms.
News
-
-
Families and care teams face obstacles to shared decision-making in DMD
The lack of clear information combined with the limited treatments for DMD impact shared decision making between families and providers.
-
New study shines light on DMD symptoms in women
A new study suggests that some female carriers of Duchenne muscular dystrophy (DMD) mutations experience symptoms and complications.
-
Death of teenager underscores risks of gene therapy treatments
A 16-year-old boy with Duchenne muscular dystrophy (DMD) died of acute liver failure several months after receiving Elevidys, a gene therapy.
-
Review examines risks of general anesthesia, neuromuscular blocking agents in DMD
A recent systematic review highlighted the risks associated with various anesthetic techniques in patients with DMD.
-
Parents of children with DMD experience moderate posttraumatic growth
Parents of patients with DMD exhibit some positive psychological and emotional growth, but would benefit from better support systems.
-
Social life the main challenge in shifting to adulthood with DMD, study finds
Young adults with DMD want to live meaningful, independent adult lives, but face challenges in social participation.
-
Novel gene variants shed light on muscular dystrophy diagnosis
Researchers identified two previously unreported mutations in the Dystrophin gene, providing new insights into muscular dystrophy.
-
Walking associated with better cardiac function in DMD
Patients with Duchenne muscular dystrophy (DMD) who can walk beyond the age of 12 appear to have better cardiac function during adulthood.
-
Study identified differences in DMD treatment across ethnicities
Patients of different racial and ethnic backgrounds with DMD received different treatments and had varying health care costs.
